Current HIV/AIDS Reports

, Volume 6, Issue 3, pp 139–145 | Cite as

Tuberculous meningitis in HIV-infected individuals



HIV-infected individuals are at increased risk for all forms of extrapulmonary tuberculosis, including tuberculous meningitis. This risk is increased at more advanced levels of immunosuppression. The time interval between onset of symptoms and presentation to medical care may vary widely, and consequently individuals may present with acute or chronic meningitis. The clinical presentation of tuberculous meningitis in HIV-infected individuals is more likely to include an altered level of consciousness, cranial imaging is more likely to show cerebral infarctions, and the yield of culture of cerebrospinal fluid may also be greater. Given that delayed initiation of therapy is a strong predictor of mortality in cases of tuberculous meningitis, clinicians must consider tuberculosis in the differential diagnosis of the HIV-infected individual with acute or chronic lymphocytic meningitis. Additional treatment considerations for HIV-infected individuals include the timing of initiation of antiretroviral therapy, the potential for drug-drug interactions, and the role of adjunctive corticosteroid therapy.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    El Sahly HM, Teetter LD, Pan X, et al.: Mortality associated with central nervous system tuberculosis. J Infect 2007, 55:502–509.PubMedCrossRefGoogle Scholar
  2. 2.
    Kilpatrick ME, Girgis NI, Yasssin MW, Abe el Ella AA: Tuberculous meningitis—clinical and laboratory review of 100 patients. J Hyg (Lond) 1986, 96:231–238.Google Scholar
  3. 3.
    Rock RB, Olin M, Baker CA, et al.: Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008, 21:243–261.PubMedCrossRefGoogle Scholar
  4. 4.
    MacGregor G: Tuberculosis of the central nervous system, with special reference to tuberculous meningitis. J Path Bacteriol 1937, 45:613–645.CrossRefGoogle Scholar
  5. 5.
    Rich AR, McCordock HA: Pathogenesis of tubercular meningitis. Bull John Hopkins Hosp 1933, 52:5–13.Google Scholar
  6. 6.
    Donald PR, Schaaf HS, Schoeman JF: Tuberculous meningitis and miliary tuberculosis: the Rich focus revisited. J Infect 2005, 50:193–195.PubMedCrossRefGoogle Scholar
  7. 7.
    Corbett EL, Watt CJ, Walker N, et al.: The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163:1009–1021.PubMedCrossRefGoogle Scholar
  8. 8.
    Selwyn PA, Hartel D, Lewis VA, et al.: A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545–550.PubMedGoogle Scholar
  9. 9.
    De Cock KM, Soro B, Coulibaly IM, Lucas SB: Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992, 268:1581–1587.PubMedCrossRefGoogle Scholar
  10. 10.
    Rana FS, Hawken MP, Mwachari C, et al.: Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000, 24:23–29.PubMedGoogle Scholar
  11. 11.
    Berenguer J, Moreno S, Laguna F, et al.: Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992, 326:668–672.PubMedGoogle Scholar
  12. 12.
    Sanchez-Portocarrero J, Perez-Cecilia E, Jimenez-Escrig A, et al.: Tuberculous meningitis. Clinical characteristics and comparison with cryptococcal meningitis in patients with human immunodeficiency virus infection. Arch Neurol 1996, 53:671–676.PubMedGoogle Scholar
  13. 13.
    Bergemann A, Karstaedt AS: The spectrum of meningitis in a population with high prevalence of HIV disease. Q J Med 1996, 89:499–504.Google Scholar
  14. 14.
    Leonard JM, Des Prez RM: Tuberculous meningitis. Infect Dis Clin North Am 1990, 4:769–787.PubMedGoogle Scholar
  15. 15.
    Verdon R, Chevret S, Laissy JP, Wolff M: Tuberculous meningitis in adults: review of 48 cases. Clin Infect Dis 1996, 22:982–988.PubMedGoogle Scholar
  16. 16.
    Girgis NI, Sultan Y, Farid Z, et al.: Tuberculosis meningitis, Abbassia Fever Hospital-Naval Medical Research Unit No. 3-Cairo, Egypt, from 1976 to 1996. Am J Trop Med Hyg 1998, 58:28–34.PubMedGoogle Scholar
  17. 17.
    Uysal G, Kose G, Guven A, Diren B: Magnetic resonance imaging in diagnosis of childhood central nervous system tuberculosis. Infection 2001, 29:148–153.PubMedCrossRefGoogle Scholar
  18. 18.
    Thwaites GE, Tran TH: Tuberculous meningitis: many questions, too few answers. Lancet Neurol 2005, 4:160–170.PubMedGoogle Scholar
  19. 19.
    Garg RK: Tuberculosis of the central nervous system. Postgrad Med J 1999, 75:133–140.PubMedGoogle Scholar
  20. 20.
    Bernaerts A, Vanhoenacker FM, Parizel PM, et al.: Tuberculosis of the central nervous system: overview of neuroradiological findings. Eur Radiol 2003, 13:1876–1890.PubMedCrossRefGoogle Scholar
  21. 21.
    Kent SJ, Crowe SM, Yung A, et al.: Tuberculous meningitis: a 30-year review. Clin Infect Dis 1993, 17:987–994.PubMedGoogle Scholar
  22. 22.
    Lu CH, Chang WN, Chang HW: The prognostic factors of adult tuberculous meningitis. Infection 2001, 29:299–304.PubMedCrossRefGoogle Scholar
  23. 23.
    Delage G, Dusseault M: Tuberculous meningitis in children: a retrospective study of 79 patients, with an analysis of prognostic factors. Can Med Assoc J 1979, 120:305–309.PubMedGoogle Scholar
  24. 24.
    van der Weert EM, Hartgers NM, Schaaf HS, et al.: Comparison of diagnostic criteria of tuberculous meningitis in human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2006, 25:65–69.PubMedCrossRefGoogle Scholar
  25. 25.
    Katrak SM, Shembalkar PK, Bijwe SR, Bhandarkar LD: The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection. J Neurol Sci 2000, 181:118–126.PubMedCrossRefGoogle Scholar
  26. 26.
    Thwaites GE, Nguyen DB, Nguyen HD, et al.: Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351:1741–1751.PubMedCrossRefGoogle Scholar
  27. 27.
    Dube MP, Holtom PD, Larsen RA: Tuberculous meningitis in patients with and without human immunodeficiency virus infection. Am J Med 1992, 93:520–524.PubMedCrossRefGoogle Scholar
  28. 28.
    Yechoor VK, Shandera WX, Rodriguez P, Cate TR: Tuberculous meningitis among adults with and without HIV infection. Experience in an urban public hospital. Arch Intern Med 1996, 156:1710–1716.PubMedCrossRefGoogle Scholar
  29. 29.
    Karstaedt AS, Valtchanova S, Barriere R, Crewe-Brown HH: Tuberculous meningitis in South African urban adults. Q J Med 1998, 91:743–747.Google Scholar
  30. 30.
    Schutte CM: Clinical, cerebrospinal fluid and pathological findings and outcomes in HIV-positive and HIV-negative patients with tuberculous meningitis. Infection 2001, 29:213–217.PubMedCrossRefGoogle Scholar
  31. 31.
    Karande S, Hupta V, Kulkarni M, et al.: Tuberculous meningitis and HIV. Indian J Pediatr 2005, 72:755–760.PubMedCrossRefGoogle Scholar
  32. 32.
    Cecchini D, Ambrosioni J, Brezzo C, et al.: Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS 2007, 21:373–374.PubMedCrossRefGoogle Scholar
  33. 33.
    Bossi P, Reverdy O, Caumes E, et al.: Tuberculous meningitis: clinical, biological and x-ray computed tomographic comparison between patients with or without HIV infection [in French]. Presse Med 1997, 26:844–847.PubMedGoogle Scholar
  34. 34.
    Thwaites GE, Duc Bang N, Huy Dung N, et al.: The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis 2005, 192:2134–2141.PubMedCrossRefGoogle Scholar
  35. 35.
    Thwaites GE, Chau TT, Caws M, et al.: Isoniazid resistance, mycobacterial genotype and outcome in Vietnamese adults with tuberculous meningitis. Int J Tuberc Lung Dis 2002, 6:865–871.PubMedGoogle Scholar
  36. 36.
    Thwaites GE, Chau TT, Farrar JJ: Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol 2004, 42:378–379.PubMedCrossRefGoogle Scholar
  37. 37.
    Puccioni-Sohler M, Brandao CO: Factors associated to the positive cerebrospinal fluid culture in the tuberculous meningitis. Arq Neuropsiquiatr 2007, 65:48–53.PubMedGoogle Scholar
  38. 38.
    Ellard GA, Humphries MJ, Allen BW: Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis 1993, 148:650–655.PubMedGoogle Scholar
  39. 39.
    van Loenhout-Rooyackers JH, Keyser A, Laheij RJ, et al.: Tuberculous meningitis: is a 6-month treatment regimen sufficient? Int J Tuberc Lung Dis 2001, 5:1028–1035.PubMedGoogle Scholar
  40. 40.
    American Thoracic Society, CDC, Infectious Diseases Society of America: Treatment of tuberculosis. MMWR Recomm Rep 2003, 52:1–77.Google Scholar
  41. 41.
    Harries AD, Hargreaves NJ, Kemp J, et al.: Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 2001, 357:1519–1523.PubMedCrossRefGoogle Scholar
  42. 42.
    El-Sadr WM, Tsiouris SJ: HIV-associated tuberculosis: diagnostic and treatment challenges. Semin Respir Crit Care Med 2008, 29:525–531.PubMedCrossRefGoogle Scholar
  43. 43.
    Li J, Munsiff SS, Driver CR, Sackoff J: Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997–2000. Clin Infect Dis 2005, 41:83–91.PubMedCrossRefGoogle Scholar
  44. 44.
    Vernon A, Burman W, Benator D, et al.: Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999, 353:1843–1847.PubMedCrossRefGoogle Scholar
  45. 45.
    Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al.: Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004, 48:4473–4475.PubMedCrossRefGoogle Scholar
  46. 46.
    Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al.: Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004, 38:280–283.PubMedCrossRefGoogle Scholar
  47. 47.
    Thwaites GE, Caws M, Chau TT, et al.: Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy. J Clin Microbiol 2004, 42:996–1002.PubMedCrossRefGoogle Scholar
  48. 48.
    Thwaites GE, Lan NT, Dung NH, et al.: Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005, 192:79–88.PubMedCrossRefGoogle Scholar
  49. 49.
    Daikos GL, Cleary T, Rodriguez A, Fischl MA: Multidrug-resistant tuberculous meningitis in patients with AIDS. Int J Tuberc Lung Dis 2003, 7:394–398.PubMedGoogle Scholar
  50. 50.
    Afghani B, Lieberman JM: Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis 1994, 19:1092–1099.PubMedGoogle Scholar
  51. 51.
    Karim SA, Naidoo K, Grobler A, et al.: Initiating ART during TB treatment significantly increases survival: results of a randomized controlled clinical trial in TB/HIV-co-infected patients in South Africa. Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8–11, 2009.Google Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Division of Infectious DiseaseHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations